Drug
Adomeglivant clinical trials
Also written LY2409021.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
15 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
Eli Lilly and Company (14) · University Hospital, Gentofte, Copenhagen (1)
Studies
Open first, then newest update. How each study uses adomeglivant is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study of LY2409021 in Participants With Type 2 Diabetes MellitusTerminatedPhase 2Eli Lilly and CompanyNCT02111096Written as LY2409021
- A Study of LY2409021 Formulations and the Effect of FoodCompletedPhase 1Eli Lilly and CompanyNCT01354496Written as LY2409021 Reference Form
- The Effects of LY2409021 on the LiverCompletedPhase 1Eli Lilly and CompanyNCT01588366Written as LY2409021
- A Study on the Effects of LY2409021 on the Electrical Impulses of the HeartCompletedPhase 1Eli Lilly and CompanyNCT01460368Written as LY2409021
- A Study of LY2409021 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02217618Written as LY2409021
- Study of LY2409021 in Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01640834Written as LY2409021
- A Study of LY2409021 in Participants With Different Levels of Kidney FunctionCompletedPhase 1Eli Lilly and CompanyNCT01929109Written as LY2409021
- A Study of LY2409021 Formulations in Healthy ParticipantsTerminatedPhase 1Eli Lilly and CompanyNCT02385084Written as LY2409021
- A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes MellitusCompletedPhase 2Eli Lilly and CompanyNCT02091362Written as LY2409021
- A Study for Participants With Type 2 Diabetes MellitusCompletedPhase 2Eli Lilly and CompanyNCT00871572Written as LY2409021
- A Study of LY2409021 in Patients With Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT01241448Written as LY2409021
- Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 DiabetesCompletedNot applicableUniversity Hospital, Gentofte, CopenhagenNCT02669524Written as LY2409021
- The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01606423Written as LY2409021
- A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01606397Written as LY2409021
- A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01606371Written as LY2409021
Given in every arm · 1 — adomeglivant is usual care beside what is tested
Codes
What other systems call adomeglivant · ClinicalTrials.gg INT000319
- MeSH (NLM) C000601762adomeglivantOne source NLM
- UNII (FDA) 74Z5ZL2KVGADOMEGLIVANTConfirmed FDA, NLM, Wikidata
- UNII (FDA) ARJ19Y7111ADOMEGLIVANT, (+/-)-Confirmed NLM, Wikidata
- UNII (FDA) RIM88PH2RAADOMEGLIVANT, (+)-Confirmed NLM, Wikidata
- Wikidata Q27266313adomeglivantConfirmed FDA, NLM, Wikidata
- Wikidata Q27274085(+/-)-adomeglivantConfirmed NLM, Wikidata
- Wikidata Q27288135(+)-adomeglivantConfirmed NLM, Wikidata
- NCI Thesaurus C166989AdomeglivantOne source FDA
- DrugBank DB11704One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601762 | adomeglivant | One source NLM |
| UNII (FDA) | 74Z5ZL2KVG | ADOMEGLIVANT | Confirmed FDA, NLM, Wikidata |
| UNII (FDA) | ARJ19Y7111 | ADOMEGLIVANT, (+/-)- | Confirmed NLM, Wikidata |
| UNII (FDA) | RIM88PH2RA | ADOMEGLIVANT, (+)- | Confirmed NLM, Wikidata |
| Wikidata | Q27266313 | adomeglivant | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27274085 | (+/-)-adomeglivant | Confirmed NLM, Wikidata |
| Wikidata | Q27288135 | (+)-adomeglivant | Confirmed NLM, Wikidata |
| NCI Thesaurus | C166989 | Adomeglivant | One source FDA |
| DrugBank | DB11704 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.